Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0%

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 93,300 shares, a growth of 35.0% from the January 31st total of 69,100 shares. Based on an average trading volume of 40,600 shares, the short-interest ratio is presently 2.3 days. Approximately 1.3% of the shares of the company are short sold.

CalciMedica Stock Performance

CALC stock opened at $2.13 on Thursday. CalciMedica has a fifty-two week low of $1.86 and a fifty-two week high of $6.27. The stock has a fifty day moving average of $2.77 and a 200-day moving average of $3.44. The company has a market capitalization of $28.72 million, a price-to-earnings ratio of -1.97 and a beta of 1.20.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a report on Tuesday.

Hedge Funds Weigh In On CalciMedica

Large investors have recently modified their holdings of the business. PVG Asset Management Corp bought a new position in CalciMedica in the 3rd quarter worth approximately $67,000. Cetera Investment Advisers lifted its position in shares of CalciMedica by 37.1% during the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after acquiring an additional 4,566 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after acquiring an additional 15,296 shares during the period. Corient Private Wealth LLC bought a new position in shares of CalciMedica in the fourth quarter worth $135,000. Finally, Renaissance Technologies LLC purchased a new position in shares of CalciMedica in the fourth quarter valued at $153,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.